AlphAIAlphAI — Financial news for AI agents
seekingalpha.comNOV 31 min read$VRTX

Vertex outlines $13.15B-$13.25B 2026 revenue guidance while adding $40M-$50M from Crinetics (NASDAQ:VRTX)

Vertex Pharmaceuticals (VRTX) reported 12% year-on-year revenue growth in Q3 2026, with total revenue ranging from $13.15B to $13.25B. The company added $40M-$50M from Crinetics. CEO Reshma Kewalramani highlighted strong commercial results and pipeline advancements.

Original reporting
seekingalpha.com
Published Nov 3, 2026, 5:49 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 5:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$VRTX
Bullish
high confidence
Mentioned
$VRTX
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$VRTXBullishHigh
01

Why it matters

The guidance range signals confidence in pipeline and market uptake, likely prompting short‑term buying.

02

Market read

Vertex's guidance and revenue growth provide fresh, material information for traders; the stock may react positively in pre‑market trading.

03

What to watch

Potential risks from upcoming regulatory decisions or trial outcomes not reflected in the guidance.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Vertex is a leading gene‑editing and cystic fibrosis drug developer; its earnings calls are closely watched.

Company-level read

Ticker impact

$VRTXBullishHigh confidence
Context

Vertex Pharmaceuticals provided FY 2026 revenue guidance of $13.15B-$13.25B and reported Q3 revenue up 12% YoY.

Expected impact

likely upward pressure as investors price in higher revenue outlook

Evidence & confidence

The new multi‑billion guidance is a primary disclosure for a large‑cap biotech and directly influences valuation.

Market effects

Sector

Biotech sector may see a lift as a leading gene‑therapy company raises guidance.

Regional

U.S. biotech stocks could benefit from the upbeat outlook.

Global

Limited to investors tracking biotech earnings and pipeline progress.

Counterpoint

What could challenge this read

If guidance falls short of analyst consensus, the stock could face disappointment despite growth.

Key entities

  • Executive
    Reshma Kewalramani

    CEO, President & Director of Vertex, quoted on earnings call.

Read at source← All news

StoryVertex raises 2026 revenue outlook after strong Q3 results and Crinetics acquisition

Also covered by

5 outlets

Related articles

NOV 3
$VRTXMedAI 8/10

Vertex: Q3 Earnings Snapshot

Vertex Pharmaceuticals (VRTX) reported Q3 profit of $653.6M, or $2.56 per share, missing estimates of $4.92 per share. Revenue was $3.44B, exceeding forecasts of $3.4B. The company expects full-year revenue between $13.15B and $13.25B.

finance.yahoo.com2 min
NOV 3
$VRTXHighAI 8/10

Vertex Pharmaceuticals Q3 Earnings Call Highlights

Vertex Pharmaceuticals raised its full-year revenue guidance to $13.15B-$13.25B, citing contributions from Crinetics. Q3 saw $2B in revenue from ALYFTREK, CASGEVY, and JOURNAVX, with ALYFTREK leading at $706M. Vertex also reported progress in renal and cystic fibrosis pipelines, including regulatory submissions for ALYFTREK in younger children and early data for VX-828. The company ended Q3 with $9.8B in cash and investments.

finance.yahoo.com3 min
NOV 2
$VRTXMedAI 9/10

Why is Vertex Pharmaceuticals stock climbing today?

Vertex Pharmaceuticals (VRTX) stock rose 0.7% after-hours after reporting Q3 2026 results. Revenue of $3.44B beat estimates, and the company raised its full-year revenue guidance to $13.15B-$13.25B. CEO Kewalramani highlighted strong revenue growth and R&D advancements. Key products CASGEVY and JOURNAVX showed significant growth, and the company completed its acquisition of Crinetics Pharmaceuticals.

investing.com5 min
NOV 2
$VRTXMedAI 8/10

Vertex Pharma meets Q3 estimates, raises revenue guidance

Vertex Pharmaceuticals (VRTX) reported Q3 earnings of $4.76 per share, meeting estimates, and revenue of $3.44B, slightly above expectations. The company raised its 2026 revenue guidance to $13.15B-$13.25B. U.S. revenue rose 10% to $2.17B, while international revenue increased 16% to $1.27B. CASGEVY and JOURNAVX showed significant growth. Vertex completed its acquisition of Crinetics Pharmaceuticals for $9.0B.

investing.com4 min
NOV 2
$VRTXMedAI 8/10

Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction

Vertex Pharmaceuticals reported Q3 revenue of $3.44B, up 12%, driven by its newer CF drug Alyftrek. Adjusted profit was flat due to spending on new launches and the Crinetics deal. Shares rose 1.5% in after-hours trading. Non-CF revenue also increased to $168M. The company expects continued investment in new drugs to impact near-term profitability.

fool.com6 min